Starling Oncology (STLNW) Assets Average (2020 - 2026)

Starling Oncology (STLNW) has reported Assets Average for 7 consecutive years, with $173.2 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Assets Average rose 7.0% year-over-year to $173.2 million; the trailing twelve-month figure through Jun 2026 stood at $173.2 million (up 7.0% YoY), and the FY2025 full-year result was $168.7 million, down 11.67% from the prior year.
• Assets Average climbed to $173.2 million in Q2 2026 per STLNW's latest filing, from $166.4 million in the prior quarter.
• Across five years, Assets Average topped out at $272.7 million in Q4 2022 and bottomed at $161.7 million in Q3 2025.
• Historically, Assets Average has averaged $198.9 million across 5 years, with a median of $195.1 million in 2022.
• The sharpest annual moves came in 2022 and 2023: Assets Average jumped 38.16% in 2022, then dropped 21.61% in 2023.
• Over 5 years, Assets Average stood at $272.7 million in 2022, then retreated by 21.61% to $213.8 million in 2023, then decreased by 17.7% to $176.0 million in 2024, then slipped by 6.71% to $164.1 million in 2025, then gained by 5.54% to $173.2 million in 2026.
• According to Business Quant data, Assets Average over the past three periods registered $173.2 million, $166.4 million, and $164.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.